Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer

Lancet Oncol. 2021 Jun;22(6):e221. doi: 10.1016/S1470-2045(21)00275-8.

Authors

Li Xie¹, Xingwen Fan², Biyun Qian³

Affiliations

¹ Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China; Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
³ Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China. Electronic address: qianbiyun@sjtu.edu.cn.

PMID: 34087131
DOI: 10.1016/S1470-2045(21)00275-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Chemoradiotherapy / adverse effects
Humans
Lung Neoplasms* / drug therapy
Small Cell Lung Carcinoma* / drug therapy